Bristol Myers Squibb fell 5% after halting its late-stage trial of Milvexian for acute coronary syndrome. An independent data monitoring committee found the study was unlikely to meet its primary goal. The drug was being tested as an add-on to standard anti-platelet therapy. Acute coronary syndrome includes conditions such as heart attacks and unstable angina.